A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal Function

Key Inclusion Criteria: All Individuals: * Body mass index (BMI) of at least ≥ 18.0 kg/m\^2 and ≤ 40.0 kg/m\^2 at screening. * No clinically significant abnormalities on electrocardiogram (ECG) * No known Liver Disease (Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT)) ≤ 3 x upper limit of normal (ULN) at screening. Individuals with Renal Impairment (RI): * Have RI classification at screening that has been unchanged during the 90 days prior to study drug dosing. * Estimated Glomerular Filtration Rate (eGFR) must be the following (using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (Inker 2021)) based on serum creatinine as measured at the screening evaluation: * Severe RI (Groups A and B): eGFR ≥ 15 to ≤ 29 mL/min/1.73 m\^2 * Moderate RI (Group C): eGFR ≥ 30 to ≤ 59 mL/min/1.73 m\^2 * Mild RI (Group D): eGFR ≥ 60 to ≤ 89 mL/min/1.73 m\^2 * Hemoglobin ≥ 9 g/dL at screening. * Individuals with cardiovascular disease, hypertension, diabetes mellitus, hyperlipidemia, hypothyroidism, osteoporosis, and many others) may be included provided that these diseases/conditions are clinically stable. Matched Control Individuals: * Have an eGFR of at least 90 mL/min/1.73 m\^2 (using the CKD-EPI equation) based on serum creatinine as measured at screening evaluation. * Matched for sex, age (± 10 years), and BMI (± 20%, 18.0 ≤ BMI ≤ 40.0 kg/m\^2) with the respective participant in the RI group. Key Exclusion Criteria: All Individual…